Metformin

Generic Name: Metformin

Brand Names: Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo

Drug Type: Small Molecule

Chemical Formula: C_₄H_₁₁N_₅

CAS Number: 657-24-9

Unique Ingredient Identifier: 9100L32L2N

Background: Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
...

Indication: Metformin immediate-release formulations

Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.

Metformin extended-release tablet (XR)
...

Associated Conditions: Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate

Associated Therapies: -

Clinical Trials

A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin

Phase 1

Recruiting

Conditions: Healthy Volunteers

Interventions: Drug: XW003 injection
Drug: Rosuvastatin
Drug: Metformin
Drug: Warfarin
Drug: Digoxin

First Posted Date: 2024-03-28

Last Posted Date: 2024-03-28

Lead Sponsor: Hangzhou Sciwind Biosciences Co., Ltd.

Target Recruit Count: 56

Registration Number: NCT06335134

Locations: 🇨🇳
West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China

Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial

Phase 1

Not yet recruiting

Conditions: Oral Submucous Fibrosis

Interventions: Drug: Metformin Hydrochloride
Drug: betamethasone dipropionate
Drug: Pentoxifylline

First Posted Date: 2024-03-27

Last Posted Date: 2024-07-26

Lead Sponsor: Ziauddin University

Target Recruit Count: 30

Registration Number: NCT06332612

Locations: 🇵🇰
Ziauddin University, Karachi, Sindh, Pakistan

Vitamin D With Omega-3 or Metformin in Osteoarthritis

Not Applicable

Not yet recruiting

Conditions: Osteoarthritis

Interventions: Dietary Supplement: Vitamin D
Dietary Supplement: Placebo
Dietary Supplement: Omega-3
Drug: Metformin

First Posted Date: 2024-03-25

Last Posted Date: 2024-03-25

Lead Sponsor: Assiut University

Target Recruit Count: 60

Registration Number: NCT06328426

Clinical Efficacy and Adverse Reactions of Antipsychotic Treatment

Not Applicable

Completed

Conditions: Hyperprolactinemia
Metabolic Disturbance
Schizophrenia

Interventions: Drug: Metformin

First Posted Date: 2024-03-22

Last Posted Date: 2024-03-22

Lead Sponsor: Taipei Medical University Hospital

Target Recruit Count: 42

Registration Number: NCT06326840

Locations: 🇨🇳
Taipei Medical University-Wan Fang Hospital, Taipei, Taiwan

PCOS Immune Function Predicts Metformin Efficacy

Not Applicable

Recruiting

Conditions: Metformin
Immune Function
Polycystic Ovary Syndrome

Interventions: Drug: Metformin

First Posted Date: 2024-03-22

Last Posted Date: 2024-03-22

Lead Sponsor: Shanghai 10th People's Hospital

Target Recruit Count: 100

Registration Number: NCT06325956

Locations: 🇨🇳
Department of Endocrinology, Shanghai Tenth People's Hospital, Shanghai, China

Effect of Continuing Versus Holding Metformin During Hospitalizations.

Phase 4

Not yet recruiting

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Metformin

First Posted Date: 2024-03-06

Last Posted Date: 2024-03-06

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 300

Registration Number: NCT06296836

Locations: 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States

Metformin Use in Patients Undergoing Total Joint Replacement Surgery

Phase 4

Recruiting

Conditions: Hyperglycemia

Interventions: Other: Placebo
Drug: Metformin

First Posted Date: 2024-02-28

Last Posted Date: 2024-07-01

Lead Sponsor: Oregon Health and Science University

Target Recruit Count: 40

Registration Number: NCT06280274

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Effectiveness of Antidiabetic Treatment Applied in Childhood Obesity

Phase 4

Completed

Conditions: Childhood Obesity
Insulin Resistance

Interventions: Drug: Metformin

First Posted Date: 2024-02-20

Last Posted Date: 2024-02-20

Lead Sponsor: HÜMEYRA ACIKAN

Target Recruit Count: 52

Registration Number: NCT06266598

Locations: 🇹🇷
Erciyes University, Kayseri̇, Melikgazi, Turkey

A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

Phase 3

Recruiting

Conditions: Type2 Diabetes Mellitus

Interventions: Drug: Exendin-4 Fc fusion protein injection（2.4mg）
Drug: Exendin-4 Fc fusion protein injection(1.2mg）
Drug: Dulaglutide
Drug: Metformin

First Posted Date: 2024-02-14

Last Posted Date: 2024-08-22

Lead Sponsor: Beijing Dongfang Biotech Co., Ltd.

Target Recruit Count: 600

Registration Number: NCT06257966

Locations: 🇨🇳
Peking University First Hospital, Beijing, Beijing, China

Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome

Phase 4

Not yet recruiting

Conditions: Polycystic Ovary Syndrome
Non-Alcoholic Fatty Liver Disease

Interventions: Drug: Canagliflozin 100mg Tab
Drug: Metformin Hydrochloride

First Posted Date: 2024-02-13

Last Posted Date: 2024-02-13

Lead Sponsor: Ping Li,MD

Target Recruit Count: 50

Registration Number: NCT06256289

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy